Results 211 to 220 of about 39,473 (264)

Microbiological Synthesis of L-dopa

Journal of Pharmaceutical Sciences, 1974
The ability of microorganisms to convert N-carbobenzoxyl-L-tyrosine, N-tert-butyloxycarbonyl-L-tyrosine, and N-formyl-L-tyrosine into their respective N-substituted L-dopa derivatives was studied. These tyrosine derivatives were examined because of the ease with which the blocking groups may be removed.
J, Rosazza, P, Foss, M, Lemberger, C J, Sih   +3 more
openaire   +2 more sources

Is l-dopa an endogenous neurotransmitter?

Trends in Pharmacological Sciences, 1993
Since the 1960s, L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopamine, has been thought to occur in the cytoplasm of catecholaminergic neurones. L-Dopa is traditionally believed to be an inert amino acid that exerts actions and effectiveness in Parkinson's disease via its conversion to dopamine by L-aromatic amino acid decarboxylase.
Y, Misu, Y, Goshima
openaire   +2 more sources

Parkinsonism, L-Dopa and Intelligence

American Journal of Psychiatry, 1973
Although many patients with parkinsonism undergo a significant amount of intellectual impairment, several investigators, including the authors, have observed an improvement in intellectual functioning during the first year of treatment with L-dopa. Upon reexamining subjects after 30 months of treatment, however, the authors found that most of their ...
A W, Loranger, H, Goodell, F H, McDowell, J E, Lee, R D, Sweet   +4 more
openaire   +2 more sources

Effects of L-dopa in autism

Journal of Autism and Childhood Schizophrenia, 1971
A study was designed to determine if blood serotonin concentrations could be lowered in autistic children by the administration of L-dopa and, if so, to observe possible clinical or physiological changes. Following a 17-day placebo period, four hospitalized autistic boys (3, 4, 9, and 13 years of age) received L-dopa for 6 months.
E R, Ritvo, A, Yuwiler, E, Geller, A, Kales, S, Rashkis, A, Schicor, S, Plotkin, R, Axelrod, C, Howard   +8 more
openaire   +2 more sources

L-Dopa in the Treatment of Parkinsonism

Gerontologia Clinica, 2009
L-dopa is not the cure for parkinsonism, but it is the best drug available so far. All of our patients had other drugs before and they made further improvement on L-dopa. Toxic reactions appeared to be dose-dependent, but the patients did well on the optimum dosage (between 4 and 5 g daily in our series).
openaire   +2 more sources

Molecular conformation of L-DOPA

Biochemical and Biophysical Research Communications, 1970
Abstract The structure of L-DOPA, a biological precursor of melanins has been determined by a new systematic analysis of the Patterson function. Its molecular conformation is different from that so far reported for any aromatic aminoacid, peptide or related compound.
J W, Becker, Y T, Thathachari, P G, Simpson   +2 more
openaire   +2 more sources

L-DOPA IN IDIOPATHIC PARKINSONISM

The Lancet, 1969
Abstract Twenty-six patients with idiopathic parkinsonism were admitted to a " double blind " " within-patient " comparison between oral L-dopa and placebo. Twenty patients completed the programme. The intake of L-dopa was gradually increased to maximum tolerated dosage (1-8 g.
D B, Calne, G M, Stern, A S, Spiers, D R, Laurence   +3 more
openaire   +2 more sources

L‐Dopa‐Induced Asterixis

Psychiatry and Clinical Neurosciences, 1985
Abstract: Three cases with the occurrence of asterixis during the administration of L‐dopa were reported. Liver and metabolic functions were normal in all the patients. Upon the appearance of asterixis no other involuntary movements probably resulting from an excess administration of L‐dopa were observed.
I, Kobayashi, M, Osawa, K, Ohta, S, Maruyama   +3 more
openaire   +2 more sources

L-Dopa in Parkinson's Syndrome

New England Journal of Medicine, 1969
The report entitled "Modification of Parkinsonism—Chronic treatment with L-dopa," by Cotzias, Papavasiliou and Gellene in this issue, is the second publication of their work in the Journal 1 and co...
openaire   +2 more sources

L-Dopa, Dopamine, and Hypomania

American Journal of Psychiatry, 1973
Greater urinary excretion of dopamine during L-dopa administration was observed in bipolar than in unipolar depressed patients. The authors suggest that increased levels of brain dopamine may play a role in the development of hypomania and mania, since there is a tendency for bipolar patients to regularly develop hypomanic episodes during L-dopa ...
D L, Murphy, F K, Goodwin, H K, Brodie, W E, Bunney   +3 more
openaire   +2 more sources